Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy
Microlaryngoscopy, Rigid Bronchoscopy
About this trial
This is an interventional treatment trial for Microlaryngoscopy focused on measuring deeply anesthetized, ideal surgical exposure, muscle relaxation, Adults
Eligibility Criteria
Inclusion Criteria:
Microlaryngoscopy or rigid bronchoscopy for vocal cord and tracheal procedures
Age 18 years or older,
ASA physical status I-III
Ability to give written informed consent.
Exclusion Criteria:
Known or suspected neuromuscular disease/pre-existing weakness,
Creatinine clearance less than 30 ml/min
Bradycardia of less than 40 beats/min,
Pregnancy, breast feeding women
Known or suspected allergy to BRIDION® (sugammadex), neostigmine or rocuronium.
Patients with contraindications towards sugammadex, neostigmine or rocuronium
Patients included in another trial within the last 30 days
Patients with legal guardians or surrogate decision making
Patients who refuse to use non-hormonal contraceptive method or back-up method of contraception (such as condoms and spermicides) for the next 7 days if receiving sugammadex.
-
Sites / Locations
- WVU Healthcare Ruby Memorial HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Group 1
Group 2
Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes:Group 1 will receive reversal with neostigmine (0.04 mg/kg and glycopyrrolate (0.01 mg/kg)
Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes: Group2 will receive reversal with sugammadex 4mg/kg